Carlos Quezada-Ruiz, MD, FASRS

Carlos Quezada-Ruiz, MD, FASRS, joined 4DMT as SVP, Therapeutic Area Head, Ophthalmology in 2024, where he leads the early and late-stage clinical development teams tackling nAMD, DME and GA. Dr. Quezada-Ruiz is also a vitreoretinal surgeon and Assistant Professor of Ophthalmology at the Instituto de Oftalmologia Fundación Conde de Valenciana’s Retina Department in Mexico City. In addition to being an active clinician, Dr. Quezada-Ruiz has been an active drug developer for the past 10 years, working at Genentech Roche, where he served in the ophthalmology management team as Group Medical Director, Clinical Science, Product Development.

During his tenure at Genentech, he led the design, execution and readouts for U.S. and global registrational trials across different retinal diseases, including the nAMD global clinical development program for VABYSMO, leading to U.S. and global approvals and the global clinical science team for SUSVIMO, supporting its initial global filing, FDA approval and launch in nAMD, successfully leading his team through the U.S. voluntary recall and recent commercial relaunch, the DR and DME Phase 3 registrational program execution, readout and filing to the FDA earlier in 2024. In the past, Dr. Quezada-Ruiz also led the Medical Affairs team efforts for the U.S. launch of Lucentis Prefilled Syringe (PFS) and the Myopic Choroidal Neovascularization indication for LUCENTIS. Additionally, he led and contributed to the advancement of D&I strategy within the Ophthalmology Franchise, including the AAO MOM program and personalized healthcare in retina within Genentech by helping design and develop predictive models using machine learning and large language models to support drug development and clinical practice.

Dr. Quezada-Ruiz is a fellow of the American Society of Retina Specialists with over 13 years of vitreoretinal clinical practice and research in vitreoretinal diseases and surgery. Dr. Quezada-Ruiz received his M.D. from Universidad Autónoma de Coahuila in his hometown, Torreon, Mexico, and completed fellowships in Vitreoretinal Surgery, Ocular Pathology-Research, and Retinal Disease and Vitreoretinal Surgery Research from Universidad Nacional Autónoma de México, McGill University, and the California Retina Research Foundation. He obtained a CIBE from Columbia Business School, Executive Education, in 2023. He received the 2023 Roche Award of Excellence in recognition for outstanding contributions to Roche Pharmaceuticals “Vabysmo and Beyond,” Genentech’s 2023 Medical Excellence Award, the 2019 American Society of Retina Specialists Senior Honor Award, the 2016 American Society of Retina Specialists Honor Award, the 2013 Gillingham Pan-American Fellow by the Panamerican Association Of Ophthalmology and The Retina Research Foundation Of Houston, Texas and the 2013 Leonard Ellen Ocular Pathology Award by the Royal Victoria Hospital Foundation.